Evommune, Inc. EVMN
Updated: 9 Aug 2026
No signal published yet
We already track Evommune and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Evommune, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Evommune free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Evommune reported its second quarter 2026 financial results and business updates, highlighting $288.0 million in cash, cash equivalents, and investments. The company also confirmed that top-line Phase 2b data for its lead drug candidate EVO756 in atopic dermatitis is expected in September 2026.
What Firelda Watch includes for Evommune, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Evommune, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Evommune free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more